Activity of mefloquine and mefloquine derivatives against Echinococcus multilocularis

作者：Rufener Reto; Ritler Dominic; Zielinski Jana; Dick Luca; da Silva Emerson Teixeira; Araujo Adriele da Silva; Joekel Deborah Elisabeth; Czock David; Goepfert Christine; Moraes Adriana Marques; Nora de Souza Marcus Vinicius; Mueller Joachim; Mevissen Meike; Hemphill Andrew; Lundstroem Stadelmann Britta

来源：International Journal for Parasitology-Drugs and Drug Resistance, 2018, 8(2): 331-340.

DOI：10.1016/j.ijpddr.2018.06.004

• Alveolar echinococcosis
• Treatment
• Anti-malaria
• HPLC
• Drug repurposing
• Structure activity relationship

The cestode E. multilocularis causes the disease alveolar echinococcosis (AE) in humans. The continuously proliferating metacestode (larval stage) of the parasite infects mostly the liver and exhibits tumor-like growth. Current chemotherapeutical treatment options rely on benzimidazoles, which are rarely curative and have to be applied daily and life-long. This can result in considerable hepatotoxicity and thus treatment discontinuation. Therefore, novel drugs against AE are urgently needed. The anti-malarial mefloquine was previously shown to be active against E. multilocularis metacestodes in vitro, and in mice infected by intraperitoneal inoculation of metacestodes when administered at 100 mg/kg by oral gavage twice a week for 12 weeks. In the present study, the same dosage regime was applied in mice infected via oral uptake of eggs representing the natural route of infection. After 12 weeks of treatment, the presence of parasite lesions was assessed in a liver squeeze chamber and by PCR, and a significantly reduced parasite load was found in mefloquine-treated animals. Assessment of mefloquine plasma concentrations by HPLC and modeling using a two-compartment pharmacokinetic model with first-order absorption showed that > 90% of the expected steady-state levels (C-min 1.15 mg/L, C-max 2.63 mg/L) were reached. These levels are close to concentrations achieved in humans during long-term weekly dosage of 250 mg (dose applied for malaria prophylaxis). In vitro structure-activity relationship analysis of mefloquine and ten derivatives revealed that none of the derivatives exhibited stronger activities than mefloquine. Activity was only observed, when the 2-piperidylmethanol group of mefloquine was replaced by an amino group-containing residue and when the trifluoromethyl residue on position 8 of the quinoline structure was present. This is in line with the anti-malarial activity of mefloquine and it implies that the mode of action in E. multilocularis might be similar to the one against malaria.

• 出版日期2018-8